[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352728-105":59,"doc-detail-352728-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","calcium-channel-blockers-inhibit-pancreatic-neuroendocrine-neoplasms-progression-via-cav12-epigenetic-circuit","Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2-Epigenetic Circuit","","Pancreatic neuroendocrine neoplasms (pNEN) are uncommon, comprising about 2% of pancreatic neoplasms, and their progression often appears as recurrence or distal metastasis. The mechanisms driving pNEN advancement remain insufficiently defined and therapeutic options are constrained by pronounced tumor heterogeneity. Using clinicomolecular analysis, this work identifies a positive regulatory circuit linking Cav1.2-mediated calcium signaling with epigenetic control via H3K27 acetylation (H3K27ac).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/calcium-channel-blockers-inhibit-pancreatic-neuroendocrine-neoplasms-progression-via-cav12-epigenetic-circuit/352728/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/calcium-channel-blockers-inhibit-pancreatic-neuroendocrine-neoplasms-progression-via-cav12-epigenetic-circuit/352728.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in pancreatic neuroendocrine neoplasms (pNEN)?","Question",{"text":112,"@type":113},"pNEN progression, including recurrence and distal metastasis, is frequent, but the underlying mechanisms are poorly understood and treatment is challenging due to strong tumor heterogeneity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What novel mechanism is proposed by the clinicomolecular analysis?",{"text":117,"@type":113},"The study reports a positive regulatory circuit between Cav1.2-mediated calcium signaling and epigenetic control by H3K27 acetylation (H3K27ac).",{"name":119,"@type":110,"acceptedAnswer":120},"How do calcium channel blockers affect pNEN progression according to the study?",{"text":121,"@type":113},"Calcium channel blockers, especially amlodipine, inhibit pNEN progression in vitro and in vivo, and clinical administration correlates with better progression-free survival and fewer distal metastases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352728,1790501048,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nCalcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via  \nCav1.2-Epigenetic Circuit  \nYangyinhui Yu1  Qiongcong Xu1  Jinzhao Xie1  Mingjian Ma1  Xitai Huang1  Yinhao Shi1  Jiawei Zhou1  Enliang Zhu1  Ziyi Zhao1  Ning Zhang2  Zhide Liu1  Jingyuan Ye1  Xiaoyu Yin1   \n1 Department of Pancreato-Biliary Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China  2 Department of Gastroenterology &  \nHepatology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China Correspondence: Xiaoyu Yin ([yinxy@mail.sysu.edu.cn](yinxy@mail.sysu.edu.cn))  \nReceived: 29 August 2025  Revised: 19 January 2026  Accepted: 25 January 2026  \nKeywords: calcium channel blockers | calcium signaling | epigenetics | pancreatic neuroendocrine neoplasms  \nABSTRACT  \nPancreatic neuroendocrine neoplasms (pNEN) are rarely encountered, accounting for about 2% of all pancreatic neoplasms. Disease progression is frequently observed as recurrence or distal metastasis. Mechanisms underlying pNEN progression are still poorly investigated, and treatments against pNEN are challenging due to the pronounced neoplastic heterogeneity. Here, by performing clinicomolecular analysis, we report a novel mechanism of positive regulatory circuit between Cav1.2-mediated calcium signaling and epigenetic control by H3K27 acetylation (H3K27ac) . Tumor-cell-specific expression of Cav1.2 strongly contributes to disease progression and correlates with malignant biological behaviors of pNEN. Moreover, we find calcium channel blockers (CCBs), especially amlodipine, remarkably inhibit pNEN progression in vitro and in vivo. Clinically, administration of CCBs correlates with better progression-free survival (PFS) and a lower rate of distal metastasis. Our work uncovers the novel mechanism of the Cav1.2-epigenetic circuit and expands the scope of therapeutic strategy for further investigation in pNEN.  \n1  Introduction  \nPancreatic neuroendocrine neoplasms (pNEN) are rare and heterogeneous diseases originating from pancreatic neuroendocrine cells. The reported incidence of pNEN is about 1 case per 100 000 individuals and accounts for about 2% of all types of pancreatic neoplasms [1, 2] . Due to improvements in diagnostic technologies, like Gallium (68 Ga)-based Positron Emission Tomography/Computed Tomography (PET/CT), the incidence of pNEN has risen multiple times over the past few decades [3] .  \nAccording to the World Health Organization (WHO) classification of gastroenteropancreatic neuroendocrine neoplasms,  \npNEN is sub-classified as well-differentiated pancreatic neuroendocrine tumor (pNET) and poorly differentiated pancreatic neuroendocrine carcinoma (pNEC), based on the pathological evaluation of proliferation index Ki-67 and mitoses [4] . Although several neuroendocrine immunohistochemical markers, such aschromogranin A (CgA) and synaptophysin (SYP), are commonly expressed in pNEN [5], the biological behavior of which is of dramatic discrepancy due to the neoplastic heterogeneity. Such variability, including the ability of hormone secretion and distal metastasis, potential for malignant transformation, as well as molecular abnormalities, is prominent not only among different individuals, but also different sites within neoplasms [6, 7] . Treatment against pNEN remains challenging due to  \n\n| Yangyinhui Yu, Qiongcong Xu, and Jinzhao Xie contributed equally to this work.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH |\n\nAdvanced Science, 2026; 13:e16733  \n[https://doi.org/10.1002/advs.202516733](https://doi.org/10.1002/advs.202516733)  \n1 of 19  \nsuch neoplastic heterogeneity. Surgery i","cbCailoHjoFTBkII","https://ap.wps.com/l/cbCailoHjoFTBkII","pdf",6296234,"English","# Abstract\n## Introduction\n## Background and rationale","[{\"question\":\"What problem does the study address in pancreatic neuroendocrine neoplasms (pNEN)?\",\"answer\":\"pNEN progression, including recurrence and distal metastasis, is frequent, but the underlying mechanisms are poorly understood and treatment is challenging due to strong tumor heterogeneity.\"},{\"question\":\"What novel mechanism is proposed by the clinicomolecular analysis?\",\"answer\":\"The study reports a positive regulatory circuit between Cav1.2-mediated calcium signaling and epigenetic control by H3K27 acetylation (H3K27ac).\"},{\"question\":\"How do calcium channel blockers affect pNEN progression according to the study?\",\"answer\":\"Calcium channel blockers, especially amlodipine, inhibit pNEN progression in vitro and in vivo, and clinical administration correlates with better progression-free survival and fewer distal metastases.\"}]","Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2-Epigenetic Circuit | PDF",1790101139,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd3db9d3ba742aa385ce04517b5d9763.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bcba51c73ebc837628bcb686387fe53.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6873a16371b090d3a9ce0db645b375da.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/644a2bd9041b6ab05fd0b9971e0893f6.webp",980,1287]